A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
1 other identifier
observational
300
1 country
1
Brief Summary
This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 18, 2021
CompletedFirst Submitted
Initial submission to the registry
October 16, 2021
CompletedFirst Posted
Study publicly available on registry
October 28, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
March 11, 2026
March 1, 2026
6 years
October 16, 2021
March 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adverse outcomes
The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission. Adverse outcomes were defined as PE-related deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.
7 days and 30 days
Study Arms (1)
Acute pulmonary embolism
an age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
Eligibility Criteria
Chinese
You may qualify if:
- age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography
You may not qualify if:
- pregnancy
- reception of reperfusion treatment before admission
- missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shenjing Hospital of CHINA MEDICAL UNIVERSITY
Shenyang, Liaoning, China
Related Publications (2)
Gao Y, Gu Z, Wei X, Wei S, Liu Y, Zhan S, Yang J, Qi C, Qi S, Wang M, Jia D. Ventricular septum curvature ratio: a novel imaging marker to predict clinical deterioration in normotensive acute pulmonary embolism. Crit Care. 2025 Oct 31;29(1):463. doi: 10.1186/s13054-025-05708-w.
PMID: 41174707DERIVEDGao Y, Wei S, Liu Y, Yu Z, Zhan S, Yang B, Qi C, Qi S, Wang M, Jia D. Predicting Deterioration in Patients With Normotensive Acute Pulmonary Embolism Using Clinical-Imaging Features: A Multicenter Prospective Cohort Study. J Am Heart Assoc. 2025 Jul;14(13):e038984. doi: 10.1161/JAHA.124.038984. Epub 2025 Jun 27.
PMID: 40576035DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 16, 2021
First Posted
October 28, 2021
Study Start
January 18, 2021
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
March 11, 2026
Record last verified: 2026-03